Li Tang

🚀 Introducing AIDO.StructureDiffusion: our new generative module for high-fidelity molecular design, built for precision, diversity, and control. With AIDO.StructureDiffusion, researchers can generate monomers, complexes, multi-domain proteins, and antibodies, with fine-grained control over structural motifs at the residue level. It enables: → Residue-wise structural conditioning via CAT classes → Target-guided antibody and nanobody design → Immunoglobulin-specific conditioning (CDR loop length, chain locus, developability) → End-to-end generation of single-chain variable fragments (scFvs) 🔬 Trained on AFDB and RCSB PDB datasets, fine-tuned on antibody structures, this model brings advanced controllability to therapeutic protein design. Whether you're designing a novel binder or engineering antibodies, AIDO.StructureDiffusion provides the structure-aware generation capabilities needed to go from idea to candidate faster and more intelligently. Read the blog: 🔗 https://lnkd.in/eSXcjRfp

206

4 Kommentare

𝐕𝐈𝐁 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐂𝐨𝐧𝐟𝐨’𝐬 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐟𝐫𝐨𝐦 𝐆𝐏𝐂𝐑 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐭𝐨 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥-𝐬𝐭𝐚𝐠𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 Confo Therapeutics, a 2015 spin-off from VIB and the lab of Prof. Jan Steyaert (VIB-VUB center of Structural Biology) builds on pioneering work conducted in collaboration with 𝐍𝐨𝐛𝐞𝐥 𝐋𝐚𝐮𝐫𝐞𝐚𝐭𝐞 𝐏𝐫𝐨𝐟. 𝐁𝐫𝐢𝐚𝐧 𝐊𝐨𝐛𝐢𝐥𝐤𝐚 (Stanford University), which led to the first-ever stabilisation of a GPCR in its active state - a major breakthrough for this complex receptor class. What began as a scientific discovery has since evolved into a differentiated biotech platform, powered by 𝐂𝐨𝐧𝐟𝐨𝐁𝐨𝐝𝐲® and 𝐂𝐨𝐧𝐟𝐨𝐂𝐡𝐢𝐦𝐞𝐫® technologies. Under the guidance of CEO Cedric Ververken, Confo has evolved from a six-person start-up into a clinical-stage biotech with global ambitions. Highlights along the way include: 🔹A strategic partnership with Eli Lilly around their novel AT2R pain program 🔹A promising obesity program targeting GPR75 - a genetically validated GPCR in the field 🔹An in-house pipeline in endocrine diseases, focused on orphan indications for future independent commercialization 🔹A €60M Series B round and strategic use of grant funding (VLAIO, Innoviris) As Cedric puts it: "𝐖𝐞’𝐯𝐞 𝐩𝐫𝐨𝐯𝐞𝐧 𝐭𝐡𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞. 𝐍𝐨𝐰 𝐢𝐭’𝐬 𝐚𝐛𝐨𝐮𝐭 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐚𝐭 𝐢𝐧𝐭𝐨 𝐫𝐞𝐚𝐥 𝐯𝐚𝐥𝐮𝐞 - 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬, 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬, 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐝𝐞𝐚𝐥𝐬." This story is featured in our quarterly Spotlight on Innovation series, which highlights how VIB translates research into biotech ventures and therapeutic impact. 👉 Read the full blog here: https://blog.vib.be/ #biotech #GPCR #VIBspinoff #ConfoTherapeutics #obesity #pain #endocrinediseases #innovation #lifesciences

153

1 Kommentar

#Chirality | 𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝗻 𝗕𝗲𝗵𝗮𝘃𝗶𝗼𝗿: 𝗔 𝗡𝗲𝘄 𝗗𝗶𝗺𝗲𝗻𝘀𝗶𝗼𝗻 𝗶𝗻 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗔𝘀𝘆𝗺𝗺𝗲𝘁𝗿𝘆 | Chirality, a property distinguishing left from right, goes beyond structure to affect electrons in molecules, uncovering a layer of complexity previously unseen. Dr. Meng Han and Prof. Dr. Hans Jakob Wörner's team at ETH Zürich visualized and manipulated electron emission from chiral molecules in real-time, showing that chirality affects electronic behavior. This insight not only deepens our understanding of chirality but also paves the way for developing sensitive methods to determine the chirality of medical agents, investigate life's chirality origins, and advance technologies across various sectors. Using circularly polarized attosecond light pulses, the researchers measured and controlled electron movement within chiral molecules. They detected the electron ejection direction based on the molecule's chirality and the light's rotation, manipulating it through attosecond pulses and infrared light. This breakthrough offers new applications in information processing, spintronics, molecular machines, and biosensor technology, revolutionizing our interaction with the chiral world. ETH Zürich's work provides a new view on chirality, emphasizing the deep link between structure and function at the molecular level. 👉 Learn more >> https://lnkd.in/eq9UsAZD 👉 Original publication >> https://lnkd.in/gZXDMJMG 🇨🇭 Follow #ScienceSwitzerland for the latest news and emerging trends on Swiss science, technology, education, and innovation >> swissinnovation.org Follow us >> Science-Switzerland #Science | #Education | #Research | #Innovation

40